Re-evolution of the 2-phenylquinolines: Ligand-based design, synthesis, and biological evaluation of a potent new class of staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4975-4989

  Sabatini, Stefano ^a   Gosetto, Francesca ^a   Iraci, Nunzio ^a   Barreca, Maria Letizia ^a   Massari, Serena ^a   Sancineto, Luca ^a   Manfroni, Giuseppe ^a   Tabarrini, Oriana ^a   Dimovska, Mirjana ^b   Kaatz, Glenn W ^b   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [[2 (4' PROPOXYPHENYL)QUINOLIN 4 YL]OXY]ETHYL]PIPERIDIN 4 ONE; 2 (4' PROPOXYPHENYL) 4 (2 PYRIDINYLMETHOXY)QUINOLINE; 2 (4' PROPOXYPHENYL) 4 [2 (1 PYRROLIDINYL)ETHOXY]QUINOLINE; 2 (4' PROPOXYPHENYL) 4 [2 (1H PYRROL 1 YL)ETHOXY]QUINOLINE; 2 [4' (PROPYLOXY)PHENYL] 4 [(2 THIOMORPHOLIN 4 YLETHYL)OXY]QUINOLINE; 4 (1 AZABICYCLO[2.2.2]OCT 3 YLOXY) 2 (4' PROPOXYPHENYL)QUINOLINE; 4 (3 METHYLBUTOXY) 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [(1 METHYLPIPERIDIN 3 YL)OXY] 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [(2 CHLOROETHYL)OXY] 2 [4' (PROPYLOXY)PHENYL]QUINOLONE; 4 [(3 METHYLBUTYL)OXY] 2 [4' (PROPYLOXY)PHENYL]QUINOLINE; 4 [(3 METHYLBUTYL)OXY] 2 [4' (PROPYLOXY)PHENYL]QUINOLONE; 4 [2 (1 AZEPANYL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [2 (1 PIPERAZINYL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [2 (3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [2 (4 BENZYLPIPERAZIN 1 YL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLONE; 4 [2 (4 MORPHOLINYL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLINE; 4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 2(1H) ISOQUINOLINYL)ETHOXY] 2 (4' PROPOXYPHENYL)QUINOLINE HYDROCHLORIDE; ANTIINFECTIVE AGENT; CIPROFLOXACIN; ENZYME INHIBITOR; ETHIDIUM BROMIDE; N,N DIISOPROPYL N [2 [[2 (4' PROPOXYPHENYL) 4 QUINOLINYL]OXY]ETHYL]AMINE; N,N DIMETHYL 1 [[2 (4' PROPOXYPHENYL) 4 QUINOLINYL]OXY] 2 PROPANAMINE HYDROCHLORIDE; N,N DIMETHYL 2 [[2 (4' PROPOXYPHENYL) 4 QUINOLINYL]OXY] ETHANOLAMINE HYDROCHLORIDE; N,N DIMETHYL 2 [[2 (4' PROPOXYPHENYL)QUINOLIN 4 YL]OXY]PROPAN 1 AMINE HYDROCHLORIDE; N,N DIMETHYL 3 [[2 (4' PROPOXYPHENYL) 4 QUINOLINYL]OXY] 1 PROPANAMINE HYDROCHLORIDE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; PHARMACOPHORE; PLASMID; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHEMISTRY TECHNIQUES, SYNTHETIC; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; INHIBITORY CONCENTRATION 50; LIGANDS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; QUINOLINES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879559590     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400262a     Document Type: Article

References (63)

1. Spellberg, B.; Guidos, R.; Gilbert, D.; Bradley, J.; Boucher, H. W.; Scheld, W. M.; Bartlett, J. G.; Edwards, J., Jr. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America Clin. Infect. Dis. 2008, 46, 155-164
2. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1-12
3. Standing up to antimicrobial resistance. Nature. Rev. Microbiol. 2010, 8, 836.
4. Taubes, G. The bacteria fight back Science 2008, 356-361
5. Chambers, H. F. Community-associated MRSA-resistance and virulence converge N. Engl. J. Med. 2005, 352, 1485-1487
6. Moran, G. J.; Krishnadasan, A.; Gorwitz, R. J.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Talan, D. A. Methicillin-resistant S. aureus infections among patients in the emergency department N. Engl. J. Med. 2006, 355, 666-674
7. Lowy, F. D. Staphylococcus aureus infections N. Engl. J. Med. 1998, 339, 520-532
8. Carbon, C. MRSA and MRSE: is there an answer? Clin. Microbiol. Infect. 2000, 6 (Suppl 2) 17-22
9. Klein, E.; Smith, D. L.; Laxminarayan, R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 Emerg. Infect. Dis. 2007, 13, 1840-1846
10. Bancroft, E. A. Antimicrobial resistance: it's not just for hospitals JAMA, J. Am. Med. Assoc. 2007, 298, 1803-1804
11. The Bacterial Challenge: Time to React; ECDC/EMEA Joint Working Group, 2009; http://www.ecdc.europa.eu/en/publications/Publications/0909-TER-The- Bacterial-Challenge-Time-to-React.pdf (accessed June 7, 2013).
12. David, M. Z.; Daum, R. S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic Clin. Microbiol. Rev. 2010, 23, 616-687
13. Centers for Disease Control and Prevention Public Health Dispatch: Vancomycin-Resistant Staphylococcus aureus-Pennsylvania Morb. Mortal. Wkly. Rep. 2002, 51, 902
14. Lynch, A. S. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view Biochem. Pharmacol. 2006, 71, 949-956
15. Marquez, B. Bacterial efflux systems and efflux pumps inhibitors Biochimie 2005, 87, 1137-1147
16. Patel, D.; Kosmidis, C.; Seo, S. M.; Kaatz, G. W. Ethidium bromide MIC screening for enhanced efflux pump gene expression or efflux activity in Staphylococcus aureus Antimicrob. Agents Chemother. 2010, 54, 5070-5073
17. Pao, S. S.; Paulsen, I. T.; Saier, M. H., Jr. Major facilitator superfamily Microbiol. Mol. Biol. Rev. 1998, 62, 1-34
18. Yoshida, H.; Bogaki, M.; Nakamura, S.; Ubukata, K.; Konno, M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones J. Bacteriol. 1990, 172, 6942-6949
19. Kaatz, G. W.; Seo, S. M. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus Antimicrob. Agents Chemother. 1997, 41, 2733-2737
20. Neyfakh, A. A. Mystery of multidrug transporters: the answer can be simple Mol. Microbiol. 2002, 44, 1123-1130
21. Mahamoud, A.; Chevalier, J.; Alibert-Franco, S.; Kern, W. V.; Pages, J. M. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy J. Antimicrob. Chemother. 2007, 59, 1223-1229
22. Stermitz, F. R.; Lorenz, P.; Tawara, J. N.; Zenewicz, L. A.; Lewis, K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 1433-1437
23. Morel, C.; Stermitz, F. R.; Tegos, G.; Lewis, K. Isoflavones as potentiators of antibacterial activity J. Agric. Food Chem. 2003, 51, 5677-5679
24. Belofsky, G.; Percivill, D.; Lewis, K.; Tegos, G. P.; Ekart, J. Phenolic metabolites of Dalea versicolor that enhance antibiotic activity against model pathogenic bacteria J. Nat. Prod. 2004, 67, 481-484
25. Wright, G. D. Resisting resistance: new chemical strategies for battling superbugs Chem. Biol. 2000, 7, R127-R132
26. Lomovskaya, O.; Lee, A.; Hoshino, K.; Ishida, H.; Mistry, A.; Warren, M. S.; Boyer, E.; Chamberland, S.; Lee, V. J. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas Aeruginosa Antimicrob. Agents Chemother. 1999, 43, 1340-1346
27. Kvist, M.; Hancock, V.; Klemm, P. Inactivation of efflux pumps abolishes bacterial biofilm formation Appl. Environ. Microbiol. 2008, 74, 7376-7382
28. Schmitz, F. J.; Fluit, A. C.; Luckefahr, M.; Engler, B.; Hofmann, B.; Verhoef, J.; Heinz, H. P.; Hadding, U.; Jones, M. E. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother. 1998, 42, 807-810
29. Aeschlimann, J. R.; Dresser, L. D.; Kaatz, G. W.; Rybak, M. J. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus Antimicrob. Agents Chemother. 1999, 43, 335-340
30. Vidaillac, C.; Guillon, J.; Arpin, C.; Forfar-Bares, I.; Ba, B. B.; Grellet, J.; Moreau, S.; Caignard, D. H.; Jarry, C.; Quentin, C. Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus Antimicrob. Agents Chemother. 2007, 51, 831-838
31. Munoz-Bellido, J. L.; Munoz-Criado, S.; Garcia-Rodriguez, J. A. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors Int. J. Antimicrob. Agents 2000, 14, 177-180
32. Kaatz, G. W.; Moudgal, V. V.; Seo, S. M.; Hansen, J. B.; Kristiansen, J. E. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus Int. J. Antimicrob. Agents 2003, 22, 254-261
33. Kaatz, G. W.; Moudgal, V. V.; Seo, S. M.; Kristiansen, J. E. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus Antimicrob. Agents Chemother. 2003, 47, 719-726
34. Gibbons, S.; Oluwatuyi, M.; Kaatz, G. W. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus J. Antimicrob. Chemother. 2003, 51, 13-17
35. Gibbons, S. Anti-staphylococcal plant natural products Nat. Prod. Rep. 2004, 21, 263-277
36. Stavri, M.; Piddock, L. J.; Gibbons, S. Bacterial efflux pump inhibitors from natural sources J. Antimicrob. Chemother. 2007, 59, 1247-1260
37. Guz, N. R.; Stermitz, F. R.; Johnson, J. B.; Beeson, T. D.; Willen, S.; Hsiang, J.; Lewis, K. Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: structure-activity relationships J. Med. Chem. 2001, 44, 261-268
38. Samosorn, S.; Bremner, J. B.; Ball, A.; Lewis, K. Synthesis of functionalized 2-aryl-5-nitro-1 H -indoles and their activity as bacterial NorA efflux pump inhibitors Bioorg. Med. Chem. 2006, 14, 857-865
39. Sabatini, S.; Kaatz, G. W.; Rossolini, G. M.; Brandini, D.; Fravolini, A. From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump J. Med. Chem. 2008, 51, 4321-4330
40. Pieroni, M.; Dimovska, M.; Brincat, J. P.; Sabatini, S.; Carosati, E.; Massari, S.; Kaatz, G. W.; Fravolini, A. From 6-Aminoquinolone Antibacterials to 6-Amino-7-thiopyranopyridinylquinolone Ethyl Esters as Inhibitors of Staphylococcus aureus Multidrug Efflux Pumps J. Med. Chem. 2010, 53, 4466-4480
41. Sabatini, S.; Gosetto, F.; Manfroni, G.; Tabarrini, O.; Kaatz, G. W.; Patel, D.; Cecchetti, V. Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl)quinoline Derivatives As Potent Inhibitors of the S. aureus NorA Efflux Pump J. Med. Chem. 2011, 54, 5722-5736
42. Sabatini, S.; Gosetto, F.; Serritella, S.; Manfroni, G.; Tabarrini, O.; Iraci, N.; Brincat, J. P.; Carosati, E.; Villarini, M.; Kaatz, G. W.; Cecchetti, V. Pyrazolo[4,3- c ][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors J. Med. Chem. 2012, 55, 3568-3572
43. Brincat, J. P.; Carosati, E.; Sabatini, S.; Manfroni, G.; Fravolini, A.; Raygada, J. L.; Patel, D.; Kaatz, G. W.; Cruciani, G. Discovery of Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus J. Med. Chem. 2011, 54, 354-365
44. Brincat, J. P.; Broccatelli, F.; Sabatini, S.; Frosini, M.; Neri, A.; Kaatz, G. W.; Cruciani, G.; Carosati, E. Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA ACS Med. Chem. Lett. 2012, 3, 248-251
45. Pieroni, M.; Sabatini, S.; Massari, S.; Kaatz, G. W.; Cecchetti, V.; Tabarrini, O. Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives Med. Chem. Commun. 2012, 3, 1092-1097
46. Handzlik, J.; Matys, A.; Kieć-Kononowicz, K. Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus Antibiotics 2013, 2, 28-45
47. Phase version 3.3; Schrödinger, LLC: New York, 2011.
48. Kaatz, G. W.; Moudgal, V. V.; Seo, S. M.; Hansen, J. B.; Kristiansen, J. E. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus Int. J. Antimicrob. Agents 2003, 22, 254-261
49. Michalet, S.; Cartier, G.; David, B.; Mariotte, A. M.; Dijoux-Franca, M. G.; Kaatz, G. W.; Stavri, M.; Gibbons, S. N -Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 1755-1758
50. Kaatz, G. W.; Seo, S. M.; O'Brien, L.; Wahiduzzaman, M.; Foster, T. J. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus Antimicrob. Agents Chemother. 2000, 44, 1404-1406
51. Price, C. T.; Kaatz, G. W.; Gustafson, J. E. The multidrug efflux pump NorA is not required for salicylate-induced reduction in drug accumulation by Staphylococcus aureus Int. J. Antimicrob. Agents 2002, 20, 206-213
52. QikProp, version 3.4; Schrödinger, LLC: New York, 2011.
53. Neyfakh, A. A. The Multidrug Efflux Transporter of Bacillus subtilis Is a Structural and Functional Homolog of the Staphylococcus NorA Protein Antimicrob. Agents Chemother. 1992, 36, 484-485
54. MacroModel, version 9.9; Schrödinger, LLC: New York, 2011.
55. Carpio, H.; Galeazzi, E.; Greenhouse, R.; Guzmán, A.; Velarde, E.; Antonio, Y.; Franco, F.; Leon, A.; Pérez, V.; Salas, R.; Valdés, D.; Ackrell, J.; Cho, D.; Gallegra, P.; Halpern, O.; Koehler, R.; Maddox, M. L.; Muchowski, M. J.; Prince, A.; Tegg, D.; Thurber, T. C.; Van Horn, A. R.; Wren, D. Synthesis of l,2-dihydro-3 H -pyrrolo[1,2- a ]pyrrole-1-carboxylic acids and homologous pyridine and azepine analogues thereof Can. J. Chem. 1982, 60, 2295-2312
56. Maestro, version 9.2; Schrödinger, LLC: New York, 2011.
57. CombiGlide, version 2.7; Schrödinger, LLC: New York, 2011.
58. Spinks, D.; Armer, R. E.; Miller, D. J.; Rankovic, Z.; Spinks, G.; Mestres, J.; Jaap, D. R. Preparation of 1-arylsulfonyl-3-substituted indoles and indolines for the treatment of central nervous system disorders. PCT Int. Appl. WO 2003068220 A1 20030821, 2003.
59. Augustin, J.; Rosenstein, R.; Wieland, B.; Schneider, U.; Schnell, N.; Engelke, G.; Entian, K. D.; Gotz, F. Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis Eur. J. Biochem. 1992, 204, 1149-1154
60. Kaatz, G. W.; McAleese, F.; Seo, S. M. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein Antimicrob. Agents Chemother. 2005, 49, 1857-1864
61. Bateman, B. T.; Donegan, N. P.; Jarry, T. M.; Palma, M.; Cheung, A. L. Evaluation of a tetracycline-inducible promoter in Staphylococcus aureus in vitro and in vivo and its application in demonstrating the role of sigB in microcolony formation Infect. Immun. 2001, 69, 7851-7857
62. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 7th ed.; Approved Standard M7-A7; Clinical and Laboratory Standards Institute: Wayne PA, 2006.
63. Eliopoulos, G. M.; Moellering, R. C. J. Antimicrobial combinations. In Antibiotics in Laboratory Medicine; Lorian, V., Ed.; Williams and Wilkins: Baltimore, MD. 1991; pp 432-492.